SCHEMBL13395659

SCHEMBL13395659

CCOC(=O)c1cc2c3c(ccc2[nH]1)C(C)(C)CO3

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.47
▸ ALDH1A1 P00352 7/20 0.47
▸ RAB9A P51151 7/20 0.47
▸ HPGD P15428 5/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ NPC1 O15118 5/20 0.44
▸ LMNA P02545 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.44
▸ MMP13 P45452 5/20 0.44
▸ MMP2 P08253 4/20 0.44
▸ MAPT P10636 4/20 0.43
▸ GAA P10253 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ GLA P06280 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ ALOX15 P16050 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13413176 0.83 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL17918164 0.76 RAB9A (0.51) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL13395661 0.75 ALDH1A1 (0.38) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL11745635 0.73 RAB9A (0.59) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL11747833 0.73 RAB9A (0.56) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL13395586 0.73 ALDH1A1 (0.48) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL5622542 0.72 KDM4E (0.56) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL8556686 0.72 HTR1A (0.45) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL6739125 0.72 KDM4E (0.58) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL8556291 0.71 HTR1A (0.45) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2064180-B1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS MERCK SHARP & DOHME (US) 2016-07-13 — — EP disclosed
US-8557848-B2 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections MERCK SHARP & DOHME CORP. (US) 2013-10-15 — — US disclosed
US-8557848-B2 4,5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections MERCK SHARP & DOHME CORP. (US) 2013-10-15 — — US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 — — US disclosed
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION 2010-04-22 — — US disclosed
WO-2008082484-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS SCHERING CORPORATION (US) 2008-07-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100098661-A1 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS ZC3HAV1, IDO1, ZC3HAV1L KDM4E 405/4885ALDH1A1 248/4885RAB9A 1341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback